ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Xian-Jun Yu
Matched on ORCID iD 0000-0003-2187-5204; OpenAlex author ID A5100736397. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 3
- G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules-dependent manner. Co-author DOI 10.1038/s41401-024-01387-5↗
- The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis. Co-author DOI 10.1038/s41388-023-02647-0↗
- ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-018-6737-6↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hao Li · 2 shared papers, 2018–2023 · strength 0.29
- Paper The platelet pannexin 1-IL-1β axis orchestrates pancreatic ductal adenocarcinoma invasion and metastasis. DOI 10.1038/s41388-023-02647-0↗
- Paper ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal A… DOI 10.1245/s10434-018-6737-6↗
- Faliang Xing · 1 shared paper, 2025 · strength 0.25
- Yingjin Fang · 1 shared paper, 2025 · strength 0.25
- Bo Zhang · 1 shared paper, 2025 · strength 0.25
- Wei Jin · 1 shared paper, 2023 · strength 0.18
- Shirong Zhang · 1 shared paper, 2023 · strength 0.18
- Huaxiang Xu · 1 shared paper, 2023 · strength 0.18
- Liang Liu · 1 shared paper, 2023 · strength 0.18
- Wen-Quan Wang · 1 shared paper, 2018 · strength 0.11
- Shi-Rong Zhang · 1 shared paper, 2018 · strength 0.11
- Liang Liu · 1 shared paper, 2018 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.